First Ascent Biomedical Responds to ASCO Clarification on Functional Precision Medicine
ASCO Clinical Notice: ASCO Clarification on the Status of Functional Precision Medicine (FPM) | ASCO Connection
Raymond Rodriguez-Torres Appointed First Ascent Biomedical New President to Scale Functional Precision Oncology https://www.prnewswire.com/news-releases/raymond-rodriguez-torres-appointed-first-ascent-biomedical-new-president-to-scale-functional-precision-oncology-302806147.html?tc=eml_cleartime
Right to Try has given patients with life-threatening illnesses a pathway to access investigational drugs after approved options and clinical…
The article examines the limitations of traditional, protocol-driven cancer treatment and explains how AI-driven Functional Precision Medicine (FPM) is transforming…
This article discusses how cancer care remains overly dependent on one-size-fits-all protocols and population averages, which often fail individual patients…
In this episode, Jim discusses why cancer treatment often relies more on established protocols than on the biological behavior of…
In this piece, you highlighted how cancer care still relies too heavily on trial and error, leaving many patients without…
In this in-depth interview, you share powerful insights into the realities of cancer care today, addressing common misconceptions, the emotional…
First Ascent Biomedical Opens FPM Cancer Lab in Miami; Welcomes World-Class Clinical Leadership
The interview explores First Ascent Biomedical’s mission to bring personalized cancer care to patients. Through the integration of biopsy testing,…
http://AI-Driven Platform Aims to Bring Personalized Cancer Treatment to More Patients | Clinical Lab Products
The interview highlights how First Ascent Biomedical is pioneering personalized treatments for pediatric cancer. By testing hundreds of FDA-approved drugs…
This September—National Childhood Cancer Awareness Month—we’re reminded that while progress has been made, the fight is far from over. According to…
This is a TEDx presentation delivered by First Ascent’s co-founder, Dr. Diana Azzam, illustrating the power of Functional Precision Medicine….
https://reachmd.com/programs/project-oncology/personalized-oncology-in-action-advancing-care-with-functional-precision-medicine/36494/
https://reachmd.com/news/innovation-in-cancer-care-a-focus-on-patient-centered-solutions-and-research-acceleration/2475479/
First Ascent Biomedical (FA), an innovative biotech company specializing in transforming cancer treatment through functional precision medicine, is proud to…
Dr. Diana Azzam, Co-Founder of First Ascent Biomedical and Associate Professor at Florida International University (FIU), received a standing ovation…
ERIE, Pa. (March 26, 2025) — Gannon University, Saint Vincent Hospital and First Ascent Biomedical today announced a collaboration to…
First Ascent Biomedical Awarded Florida Cancer Innovation Fund Grant Grant Focused on Advancing Precision Cancer Treatment for Underserved Communities Miami,…
CancerX is a groundbreaking public-private partnership designed to accelerate innovation in the fight against cancer. Hosted by the Moffitt Cancer…
This is the first time Nature Medicine published a Functional Precision Medicine approach for treating cancer. April 2024 Nature…
Our study shows the technical feasibility of integrating functional precision medicine approaches for patients with refractory/relapsed pediatric cancers. Routine clinical…
Our studies demonstrate the potential for predictive and generative artificial intelligence and machine learning approaches to address critical challenges multi-omics,…
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform…
First Ascent Biomedical Inc., a clinical-stage functional precision medicine company advancing the novel xDRIVE (Ex Vivo Drug Response Identification and…
Inside Precision Medicine April 18, 2024 IPM interviewed Dr. Diana Azzam First Ascent co-founder and cancer researcher about her latest…
[fusion_builder_container type=”flex” hundred_percent=”no” equal_height_columns=”no” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” border_style=”solid” admin_toggled=”no”][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ background_position=”left top”…
Function Precision Medicine (FPM) and AI to provide new treatment options for minority childhood cancer patients in South Florida. Read…
Risk or presence of metastasis in medulloblastoma causes substantial treatment-related morbidity and overall mortality. Read the full publication on PubMed.
Systemic therapy for metastatic clear cell sarcoma (CCS) bearing EWSR1-CREB1/ATF1 fusions remains an unmet clinical need in children, adolescents, and…
Over the past 25 years, chemotherapy regimens for osteosarcoma have failed to improve the 65-70% long-term survival rate. Radiation therapy…
Metastatic epithelioid sarcoma (EPS) remains a largely unmet clinical need in children, adolescents and young adults despite the advent of…
The collaboration between Lucem Health, Mayo Clinic Platform, and First Ascent Biomedical will reduce complexity while developing new, or enhancing…
Moving drugs to and through phased trials, especially in cancer, is daunting and riddled with complexity. By combining engineering and…
orrectly diagnosing a rare childhood cancer such as sarcoma can be critical to assigning the correct treatment regimen. With a…
Correctly diagnosing a rare childhood cancer such as sarcoma can be critical to assigning the correct treatment regimen. With a…
Preclinical cancer research ranges from in vitro studies that are inexpensive and not necessarily reflective of the tumor microenvironment to…
Wilms tumor is the most common childhood kidney cancer. Two distinct histological subtypes of Wilms tumor have been described: tumors…
As high-throughput sequencing experiments become more widely used in pre-clinical and clinical settings, pharmacogenetic and pharmacogenomic biomarker development plays an…
Diffuse intrinsic pontine glioma (DIPG), a rare pediatric brain tumor, afflicts approximately 350 new patients each year in the United…
Specific mutations in the RET proto-oncogene are associated with multiple endocrine neoplasia type 2A, a hereditary syndrome characterized by tumorigenesis…
Diffuse intrinsic pontine glioma (DIPG) is a devastating pediatric cancer with unmet clinical need. DIPG is invasive in nature, where…
Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood with a propensity to metastasize. Read the full publication on…
Rhabdomyosarcoma (RMS) is a mesenchymal malignancy phenocopying muscle and is among the leading causes of death from childhood cancer. Read…
Rhabdomyosarcoma (RMS) is a mesenchymal malignancy phenocopying muscle and is among the leading causes of death from childhood cancer. Read…
In this case report we evaluate the genetics of and scientific basis of therapeutic options for a 14-yr-old male patient…
Nonrhabdomyosarcoma soft-tissue sarcomas (STSs) are a class of 50+ cancers arising in muscle and soft tissues of children, adolescents, and…
Rhabdomyosarcoma (RMS) is the most common childhood soft-tissue sarcoma. The largest subtype of RMS is embryonal rhabdomyosarcoma (ERMS) and accounts…
CIC-rearranged sarcomas (CRSs) have recently been characterized as a distinct sarcoma subgroup with a less favorable prognosis compared to other…
Relapsed and metastatic hepatoblastoma represents an unmet clinical need with limited chemotherapy treatment options. Read the full publication on PubMed.
Cancer patients with advanced disease routinely exhaust available clinical regimens and lack actionable genomic medicine results, leaving a large patient…
Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. Cancer patients with advanced disease…
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric cancer population. Survival among metastatic RMS patients has…
Feline injection-site sarcoma (FISS), an aggressive iatrogenic subcutaneous malignancy, is challenging to manage clinically and little is known about the…
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood with an unmet clinical need for decades. A single…
Diffuse intrinsic pontine glioma (DIPG) is a universally fatal childhood cancer of the brain. Despite the introduction of conventional chemotherapy…
In complex, highly unstable genomes such as in osteosarcoma, targeting aberrant checkpoint processes (metabolic, cell cycle or immune) may prove…
Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. RMS often arise from myogenic precursors and displays a poorly…
Design of personalized targeted therapies involve modeling of patient sensitivity to various drugs and drug combinations. Read the full publication…
The prediction of tumor sensitivity to targeted drugs remains a major challenge in the design of optimal therapeutic strategies. Read…
Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood cancer. We performed a chemical screen in patient-derived DIPG cultures along…
Diffuse intrinsic pontine gliomas (DIPGs) represent a particularly lethal type of pediatric brain cancer with no effective therapeutic options. Read…
A framework for design of personalized cancer therapy requires the ability to predict the sensitivity of a tumor to anticancer…
Drugs that target specific proteins are a major paradigm in cancer research. In this article, we extend a modeling framework…
Alveolar rhabdomyosarcoma (aRMS) is a myogenic childhood sarcoma frequently associated with a translocation-mediated fusion gene, Pax3:Foxo1a. Read the full publication…
The success of targeted anti-cancer drugs are frequently hindered by the lack of knowledge of the individual pathway of the…
Drugs targeting specific kinases are becoming common in cancer research and are a basis for personalized cancer therapy. Some of…
Genetic Regulatory Networks (GRNs) are frequently modeled as Markov Chains providing the transition probabilities of moving from one state of…